Amgen Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| AMG.DE | BIIB | NVS | 0R1F.IL | 1801.HK | REGN | |
|---|---|---|---|---|---|---|
| Market cap | 214.17B | 37.04B | 287.24B | 135.23B | 145.09B | 82.88B |
| P/E (TTM) | 28.4 | 44.5 | 22.8 | 17.0 | 109.5 | 19.9 |
| Forward P/E | — | 15.2 | 15.4 | — | 32.8 | 12.8 |
| Price/book | 20.6 | 2.0 | 6.9 | 4.1 | 5.9 | 2.5 |
| Dividend yield | 2.17% | — | 3.14% | 4.04% | — | 0.47% |
| 1-year change | +59.02% | +66.65% | +17.02% | +40.31% | −4.62% | +37.54% |
| Today | −1.16% | −1.24% | −3.30% | +2.53% | +1.96% | −1.72% |
The closest companies by business and industry (Drug Manufacturers - General). Prices may be delayed up to 15 min.
Latest news
All AMG.DE news ›Piper Sandler Remains a Buy on Amgen (AMGN)
Piper Sandler analyst David Amsellem reiterated a Buy rating on Amgen today and set a price target of $457.00. Amsellem covers the Healthcare sector, focusing on stocks such as Amgen, Corcept Therapeutics, and AbbVie. According to…
AMGEN Inc
Set by 24/7 Wall St.’s proprietary analysis of professional targets, profit trajectory, sector, risk, and retail attention. How we calculate our price targets → Amgen appears attractively valued at current levels. With a 10.0% upside to…
Amgen vs. Eli Lilly: Does the GLP-1 Mania Make LLY Stock a Better Buy in 2026?
Are you looking for a stable dividend payer or a high-growth medical innovator? Choosing between Amgen (AMGN +2.04%) and Eli Lilly & Co. (LLY +2.83%) depends on your specific goals for 2026. Amgen operates as a mature biotechnology leader…
What Changed In Amgen’s Story?
For questions about this article or underlying research, email [email protected]. Amgen Now Talks Up Six Growth Drivers And MariTide Management now builds its case around what it calls its six key growth drivers. On the fiscal Q2 2026 call,…
AstraZeneca-Amgen asthma drug hits 69% remission in esophageal disease trial
pharma.economictimes.indiatimes.com AstraZeneca-Amgen asthma drug hits 69% remission in esophageal disease trial - Published On Oct 21, 2026 at 07:17 AM IST Find this Comment Offensive? Join the community of 2M+ industry professionals. All…
Amgen and AstraZeneca report Phase III Tezspire data for EoE
Amgen and AstraZeneca have reported complete results from the Phase III CROSSING clinical trial of Tezspire (tezepelumab-ekko) for adolescent and adult patients with uncontrolled, symptomatic eosinophilic oesophagitis (EoE). Subcutaneous…
Amgen, AstraZeneca's Tezspire achieves 69% remission in Phase III EoE trial
AllSci is an AI-grounded scientific knowledge platform. It aggregates the global scientific literature, patents, grants and trials, atomizes them into hypotheses, questions, results and claims, links everything to canonical entity…
From Discovery to Delivery: 5 Ways Amgen Is Putting Sustainability into Practice
Across Amgen, teams are looking for ways to use resources efficiently, reduce costs, and improve environmental sustainability. Across research and development, packaging, transportation, and sourcing here are examples of how Amgen teams…
Amgen (NASDAQ:AMGN) Sets New 1-Year High – Should You Buy?
Posted by Tristan Rich on Oct 22nd, 2026 Amgen Inc. (NASDAQ:AMGN – Get Free Report)’s share price hit a new 52-week high during trading on Thursday. The stock traded as high as $447.37 and last traded at $446.2170, with a volume of 418,349…
Amgen And AstraZeneca Announce Full Results From Positive Phase 3 CROSSING Trial Of TEZSPIRE For Eosinophilic Esophagitis
Published on 10/20/2026 at 09:00 am EDT Key secondary endpoints assessed histologic remission and dysphagia symptoms at week 52; changes in endoscopic disease features (EREFS) and histologic severity and extent (EoE-HSS) at weeks 24 and…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
-
marketscreener.com24
-
marketbeat.com21
-
trefis.com7
-
gurufocus.com4
-
kalkinemedia.com4
Finance and business coverage in the 4Search news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 100 articles, not a forecast.